Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease
- RTX001 is the first engineered Regenerative Macrophage Therapy (RMT) to be evaluated in humans with advanced liver fibrosis
- First patient has successfully cleared safety period with no serious adverse events
- Enrolment is now open for the study, with initial data readout expected in 2026
Edinburgh and London, UK, 3 September 2025 – Resolution Therapeutics (“Resolution” or “Company”), a clinical-stage biopharmaceutical company focused on pioneering Regenerative Macrophage Therapy to treat inflammatory and fibrotic diseases, today announces that the first patient has been dosed and safety cleared in its Phase I/II EMERALD study. EMERALD is evaluating RTX001, a first-in-class engineered RMT for patients with a history of decompensated liver cirrhosis. Following this success, the study is now open for full enrolment in the UK and Spain.
